AstraZeneca PLC vs Target Corporation: Strategic Comparison

This in-depth comparison examines AstraZeneca PLC and Target Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AstraZeneca PLC on its own, evaluating Target Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AstraZeneca PLC and Target Corporation is widest.

On the headline numbers, AstraZeneca PLC reports annual revenue of $45.8B against $107.4B for Target Corporation, while their respective market capitalizations stand at $210.4B and $63.5B. AstraZeneca PLC is headquartered in United Kingdom and Target Corporation operates from United States, and those different home markets shape how each company competes.

AstraZeneca PLC: AstraZeneca makes money primarily from patented prescription medicines, plus alliance and collaboration revenue. Its scale depends on clinical development, regulatory approvals, market access, lifecycle management, and global commercial execution.

Target Corporation: Target is a retailer whose value comes from making mass retail feel curated. The business is strongest when stores, digital channels, owned brands and fulfillment services reinforce one another.

AstraZeneca PLC and Target Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AstraZeneca PLC and Target Corporation.

AstraZeneca PLC business model: AstraZeneca operates a focused, capital-intensive biopharmaceutical model concentrated on Oncology, Cardiovascular, and Respiratory diseases. Its financial engine relies entirely on funding expensive, risky clinical trials to discover distinct "blockbuster" drugs. Once an extensive drug (like Tagrisso for lung cancer) is approved, it commands astronomical price premiums, generating multi-billion-dollar high-margin cash flow globally, shielded by aggressive legal patent protection. The business model is entrenched in the high-risk, high-reward global biopharmaceutical sector, focusing exclusively on the capital-intensive discovery, development, and commercialization of complex, innovative prescription therapeutics. By specializing in advanced, specialized therapeutic areas—specifically oncology, cardiovascular/renal/metabolism (CVRM), and rare diseases—the company targets specialized medical niches characterized by unmet patient needs and significant global pricing power. This heavily targeted, science-driven approach allows the company to dynamically redirect commercial cash flows toward relentless, cutting-edge clinical research, mitigating the existential threat of patent expirations by ensuring a continuous, aggressive cadence of internal pipeline development coupled with strategic, multi-billion-dollar acquisitions.

Target Corporation business model: Target runs a general-merchandise, big-box retail model that pairs low-margin essentials (groceries, household basics) to drive store traffic with higher-margin discretionary categories (apparel, home decor, and private-label brands) to drive profit -- the classic 'basket size' strategy. Owned and exclusive brands make up a large share of sales and carry better margins than national brands, a strategy Target has leaned on more heavily to compete with Walmart's scale and Amazon's convenience. Digital and same-day fulfillment, built around the 2017 Shipt (about $550 million) and Grand Junction acquisitions, let Target use its stores as fulfillment hubs -- a model that became central to growth during the pandemic and remains core to its omnichannel strategy today. FY2025 revenue was $104.780 billion, continuing a decline from $107.412 billion in fiscal 2023, as the company worked through a sales and stock slump serious enough to trigger a CEO change; Q1 FY2026 showed a rebound, with net sales growth of 6.7% and comparable sales up 5.6%. Target's owned-brand strategy, including labels like Good & Gather and Cat & Jack, has become an increasingly important profit lever as the retailer competes against both Walmart's scale and Amazon's convenience without matching either directly. Targets fiscal 2025 results reflected the ongoing challenge of balancing inventory discipline against the risk of stockouts during a demand recovery.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AstraZeneca PLC stack up against those of Target Corporation.

AstraZeneca PLC competitive advantage: AstraZeneca's competitive position is strengthened by its integrated oncology ecosystem, rare disease complement platform, and emerging presence in weight management and cell therapy. The DAPA-HF and DAPA-CKD trials gave Farxiga a first-mover advantage in heart failure that Jardiance has since matched, but Farxiga's earlier approval and broader label have maintained its leadership position. The gross profit margin on Product Sales was 84% in 2025, reflecting higher manufacturing costs and product mix shifts, with the company targeting margin improvement through scale efficiencies and biologics mix expansion. AstraZeneca's single most defensible competitive moat is its integrated oncology ecosystem, which combines targeted small molecules, immuno-oncology biologics, antibody-drug conjugates, and radiopharmaceuticals into a portfolio that no competitor can replicate in under a decade. The company's R&D productivity metrics support this moat: AstraZeneca achieved 74 regulatory events and 24 pipeline progression events in 2024, with 16 positive Phase III readouts in 2025 and a pipeline of 186 projects including 19 new molecular entities in late-stage development. The company's geographic diversification further strengthens the moat: AstraZeneca is the number one pharmaceutical company in Emerging Markets, including China, and holds top-three positions in Europe and Japan, meaning that no single market disruption can destabilize the overall enterprise. The success of these bets depends on flawless execution across clinical development, regulatory approval, manufacturing scale-up, and commercial launch, a sequence of complex activities where any single failure could delay revenue targets by years. The spinoff gave Zeneca independence, a strong oncology portfolio, and the need to find scale it couldn't achieve alone in an industry that was consolidating globally.

Target Corporation competitive advantage: Target's advantage is the mix of curated merchandise, owned brands, convenient stores, same-day fulfillment and a brand position between discount utility and design-led retail.

Future prospects matter as much as current results. The growth strategies below explain how AstraZeneca PLC and Target Corporation each plan to expand from here.

AstraZeneca PLC growth strategy: AstraZeneca's growth strategy centers on oncology expansion, rare disease from Alexion, cardiovascular and renal medicines, respiratory and immunology launches, pipeline execution, and manufacturing/R&D investment.

Target Corporation growth strategy: Target is focusing on merchandising authority, guest experience, technology acceleration, team and community strength, stores-as-hubs, same-day fulfillment, retail media and owned-brand renewal.

A closer look at the financial trajectory of AstraZeneca PLC and Target Corporation rounds out the comparison.

AstraZeneca PLC: AstraZeneca operates as one of the most successful oncology pipelines in the global pharmaceutical industry. Under the long-tenured leadership of CEO Pascal Soriot, the British-Swedish multinational generated exactly $45.8 billion in revenue and maintains a $210.4 billion market cap with exactly 89900 employees. Having fully moved past the zero-margin distribution of its COVID-19 vaccine, AstraZeneca's financial narrative in 2026 is entirely driven by its blockbuster cancer drugs (specifically Tagrisso, Enhertu, and Imfinzi). the company has integrated its $39 billion acquisition of Alexion Pharmaceuticals, giving it a dominant, high-margin foothold in the rare disease space.

Target Corporation: Target is fighting a critical battle to restore traffic momentum and recapture the discretionary spending that migrated to Walmart and Amazon during the damaging inventory and brand perception crises of recent years. Under CEO Brian Cornell, the retail giant generated exactly $107.4 billion in revenue and maintains a $63.5 billion market cap with exactly 415000 employees. The financial narrative in 2026 is entirely defined by discretionary category reinvestment; rebuilding its coveted premium value reputation, Target extracts improving same-store sales by furiously expanding its differentiated owned brands, investing in store experience, and optimizing its same-day fulfillment through its beloved Drive Up and Shipt services.